Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q1 2024 U.S. Biopharma Recap

Biopharma’s rebound came into full effect in Q1 2024. Major biopharma indices extended their year-end rally helping lay the foundation for an extremely active quarter for public financings with 105 total offerings (including IPOs, follow-ons, PIPEs and RDs), raising a total of $18.7 billion. Both totals were the highest since the first quarter of 2021. Additionally, the private financing market skewed later-stage and “crossovers” became more common thanks to a reopening IPO window.

Meanwhile, big pharma’s appetite for deal making continued with eight acquisitions announced over $1 billion in deal value and 10 partnering deals announced with more than $50 million in upfront proceeds this quarter. Although, some market participants worry the recovery has been too swift, and the U.S. presidential election looms large for overall market health, the stage remains set for a much more favorable 2024 for biopharma.

William Blair's biopharma team shares additional perspectives on the biopharma environment in Q1 2024 and what to expect for the remainder of the year.

Complete the form below to download a copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Navigating a Dynamic Lending Market With an Outside Debt Advisor

    Traversing the vast and ever-changing lending market is no easy task—especially given how much lenders vary when it comes to appetites and terms.

    Read more
  • FMX Has Received a Strategic Growth Investment from Luminate Capital Partners

    William Blair acted as exclusive financial advisor to FMX in connection with its strategic growth investment from Luminate Capital Partners.

    Read more
  • Ortholite Has Agreed to be Acquired by Coats Group plc

    William Blair acted as the lead financial advisor to Ortholite, a portfolio company of Trilantic Capital Partners, in connection with its pending sale to Coats Group plc (LSE: COA) for an enterprise value of $770 million excluding value ascribed to tax attributes and a royalty agreement for recently introduced intellectual property that was yet to be commercialized in the market.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures